CVRx, Inc.
CVRXNasdaq
$4.91
↓ -8.9%Jul 17 close · end-of-day
Price
1Y↓ -41.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$129.4M
Enterprise Value
$115.6M
P/E
—
P/S
2.2
P/B
4.4
EV/EBITDA
—
PEG
—
FCF Yield
-31.0%
Dividend Yield
—
Revenue (TTM)
$59.1M
Net Income (TTM)
-$52.7M
Free Cash Flow (TTM)
-$40.2M
Gross Margin
86.2%
Operating Margin
-84.6%
Net Margin
-89.1%
ROE
-180.9%
ROIC
-258.2%
Debt / Equity
2.0
Net Cash
$13.8M
Return 1Y
-41.2%
Company profile
CVRx, Inc. focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe and internationally.
- CEO
- Nadim Yared
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 160
- Headquarters
- Minnesota
- Website
- cvrx.com
Management & directors
- Adamson Philip B.Chief Medical Officer
- Hykes KevinPRES & CEO
- John Robert AllenChief Revenue Officer
- Morrison GregoryCHIEF HUMAN RESOURCES OFFICER
- Oasheim JaredCHIEF FINANCIAL OFFICER
- Verrastro PaulCHIEF MKTG & STRAT OFFICER
- Binkowski BrentCHIEF OPERATING OFFICER
Roles derived from SEC Form 4 filings.
Earnings
CVRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$14.8M↑ +19.6%
Diluted EPS-$0.50↓ -5.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.1M | $13.0M | $22.5M | $39.3M | $51.3M | $56.7M |
| Gross profit | $4.6M | $9.4M | $17.5M | $33.0M | $43.0M | $48.3M |
| Operating income | -$11.5M | -$26.0M | -$42.5M | -$43.1M | -$59.5M | -$51.3M |
| Net income | -$14.1M | -$43.1M | -$41.4M | -$41.2M | -$60.0M | -$53.3M |
| Diluted EPS | — | -$4.16 | -$2.02 | -$1.99 | -$2.65 | -$2.04 |
| Operating cash flow | -$16.1M | -$27.7M | -$42.7M | -$39.0M | -$39.1M | -$40.2M |
| Free cash flow | -$16.4M | -$28.9M | -$43.4M | -$39.6M | -$40.5M | -$40.8M |
| Gross margin | 76.2% | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% |
| Operating margin | -190.2% | -199.2% | -189.3% | -109.7% | -116.0% | -90.5% |
| Net margin | -233.1% | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.8M | $13.4M | $15.3M | $12.3M | $13.6M | $14.7M | $16.0M | $14.8M |
| Gross profit | $9.9M | $11.1M | $12.8M | $10.3M | $11.4M | $12.8M | $13.8M | $12.9M |
| Operating income | -$14.0M | -$13.0M | -$10.3M | -$13.4M | -$14.4M | -$12.3M | -$11.2M | -$12.2M |
| Net income | -$14.0M | -$13.1M | -$10.7M | -$13.8M | -$14.7M | -$12.9M | -$11.9M | -$13.1M |
| Diluted EPS | -$0.65 | -$0.57 | -$0.39 | -$0.53 | -$0.57 | -$0.49 | -$0.45 | -$0.50 |
| Operating cash flow | -$9.8M | -$10.4M | -$8.0M | -$12.8M | -$7.9M | -$9.7M | -$9.8M | -$12.2M |
| Free cash flow | -$10.2M | -$10.4M | -$8.1M | -$12.9M | -$8.0M | -$10.0M | -$9.8M | -$12.3M |
| Gross margin | 83.9% | 83.2% | 83.2% | 83.5% | 84.3% | 86.8% | 86.3% | 87.2% |
| Operating margin | -118.3% | -97.3% | -67.0% | -108.8% | -105.8% | -83.5% | -69.8% | -82.3% |
| Net margin | -118.8% | -98.0% | -69.4% | -111.5% | -108.4% | -87.6% | -74.5% | -88.8% |
Company news
May 27, 2026
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Nielsen Kirk G. | Award | 8,720 | $0.00 | $0.00 | filing |
| 2026-06-01 | Jain Mudit K. | Award | 8,720 | $0.00 | $0.00 | filing |
| 2026-06-01 | SLATTERY JOSEPH P | Award | 8,720 | $0.00 | $0.00 | filing |
| 2026-06-01 | Hill, Mitch C. | Award | 8,720 | $0.00 | $0.00 | filing |
| 2026-06-01 | Ballinger Kevin J. | Award | 8,720 | $0.00 | $0.00 | filing |
| 2026-06-01 | SHADAN MARTHA | Award | 8,720 | $0.00 | $0.00 | filing |
| 2026-06-01 | DALE MICHAEL D | Award | 29,005 | $0.00 | $0.00 | filing |
| 2026-03-02 | Hykes Kevin· PRES & CEO | Sale | 7,763 | $7.90 | $61,348.66 | filing |
| 2026-03-02 | John Robert Allen· Chief Revenue Officer | Sale | 3,964 | $7.90 | $31,325.51 | filing |
| 2026-03-02 | OASHEIM JARED· CHIEF FINANCIAL OFFICER | Sale | 1,744 | $7.90 | $13,781.44 | filing |
| 2026-03-02 | VERRASTRO PAUL· CHIEF MKTG & STRAT OFFICER | Sale | 1,284 | $7.90 | $10,146.30 | filing |
| 2026-03-02 | Adamson Philip B.· Chief Medical Officer | Sale | 1,262 | $7.90 | $9,973.21 | filing |
| 2026-03-02 | Morrison Gregory· CHIEF HUMAN RESOURCES OFFICER | Award | 34,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | Adamson Philip B.· Chief Medical Officer | Award | 41,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | Hykes Kevin· PRES & CEO | Award | 159,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | VERRASTRO PAUL· CHIEF MKTG & STRAT OFFICER | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | OASHEIM JARED· CHIEF FINANCIAL OFFICER | Award | 61,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | John Robert Allen· Chief Revenue Officer | Award | 35,000 | $0.00 | $0.00 | filing |
| 2026-02-27 | Binkowski Brent· CHIEF OPERATING OFFICER | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Jain Mudit K. | Buy | 46,800 | $6.36 | $297,591.84 | filing |
| 2026-02-18 | Jain Mudit K. | Buy | 600 | $4.64 | $2,785.02 | filing |
| 2025-11-26 | JOHNSON & JOHNSON | Sale | 6,337 | $10.03 | $63,560.11 | filing |
| 2025-11-26 | JOHNSON & JOHNSON | Sale | 6,337 | $10.03 | $63,560.11 | filing |
| 2025-11-25 | JOHNSON & JOHNSON | Sale | 16,000 | $10.03 | $160,480.00 | filing |
| 2025-11-24 | JOHNSON & JOHNSON | Sale | 2,200 | $10.06 | $22,132.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.